1 in 3 Malaysian adults are overweight or obese, also one of the highest obesity rates in ASEAN. <br /><br />Additionally, obesity-linked NCDs are already costing the economy billions in lost productivity each year.<br /><br />With Obesity Management Medicines (OMMs) such as GLP-1s reshaping weight care globally and Malaysia’s obesity management market projected to nearly double by 2031 - how do we integrate these therapies safely, equitably and responsibly?<br /><br />NIAGA SPOTLIGHT features Binh Thai, General Manager, Commercialization – Malaysia, Singapore and Brunei, Zuellig Pharma and Prof Dr Rohana Abdul Ghani, Consultant Endocrinologist and President, Malaysian Obesity Society (MYOS) for this timely conversation. <br />
